What is the Share Price of Syncom Formulations (India) Ltd?
- Answer Field
-
The share price of Syncom Formulations (India) Ltd for NSE is ₹ 16.32 and for BSE is ₹ 16.4.
BAJAJ BROKING
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, SYNCOM FORMU (I) LTD share price is currently at ₹ 16.32, which is down by ₹ -0.48 from its previous closing. Today, the stock has fluctuated between ₹ 16.25 and ₹ 16.89. Over the past year, SYNCOM FORMU (I) LTD has achieved a return of 21.37 %. In the last month alone, the return has been -1.75 %. Read More...
Particulars | DEC 2024 (Values in Cr) |
---|---|
Revenue | 127.03 |
Operating Expense | 113.94 |
Net Profit | 12.79 |
Net Profit Margin (%) | 10.06 |
Earnings Per Share (EPS) | 0.14 |
EBITDA | 18.41 |
Effective Tax Rate (%) | 24.31 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 37.10 | 19.95 | 2.02 | 284.31 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 122.65 | 16.07 | 1.27 | 1292.37 | 92.25 / 184.95 |
CIPLA LTD | 1541.00 | 24.94 | 4.38 | 124457.39 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 272.25 | 22.56 | 2.76 | 801.26 | 145.00 / 449.00 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 37.10 | 22.35 | 6.30 | 284.31 | 34.11 / 77.70 |
AMRUTAJAN HEALTH LTD | 679.10 | 39.81 | 6.59 | 1963.32 | 548.05 / 861.40 |
ASTRAZENECA PHARMA IND LT | 8795.90 | 131.18 | 32.36 | 21989.75 | 5000.00 / 9199.00 |
BLISS GVS PHARMA LTD | 122.65 | 15.93 | 1.26 | 1292.37 | 92.25 / 184.95 |
Incorporated as a private limited company in 1988, Syncom Formulations (India) Limited was converted into a public limited company in Jun.'92. The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency. Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh.
Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards. Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers.
The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations. Commercial production commenced in Apr.'89. Promoters are Kedarmal Bankda, Vijay Kumar Bankda and Ajay Kumar Bankda.
In addition to pharmaceutical formulations in the form of tablets, capsules, liquids and dry powders, the company also manufactures injectibles and ear/eye drops on a loan licence basis.
In 1994, the company undertook an expansion programme of setting up a new plant for manufacturing pharmaceutical formulations at Pithampur, Madhya Pradesh. The project which was financed through a public issue made in Jan.'94 was completed in 1995.
During the year 1997-98, the Company has further diversified into Ethical Operations by introducing the range of prescription formulations.
During the year 1998-99 there has been huge expansion of installed capacity and production base. Further the company plans introduction of products in the generic, OTC and Ethical Divisions. The export earnings have also registered a growth of more than 100%.
During the year 1999-2000, the company and its associates have received export orders worth Rs.700.00 lacs against advance payment and hence better turnover is expected during the year. The company presently exports goods to Guine, Ghana, Kenya, Tanzania, Nigeria in Africa, Azberjan, Nepal and Srilanka in Asia. The company has been approved as a supplier to Central ESI Hospitals and registration of defence services is in its final stages, as a result of which will generate substantial sales volume. Keeping in view the shifting consumer preferenes for the use of herbal products, the company is aggressively manufacturing and marketing its herbal products like Edicare, Attom Megacaps, Ecziguard and Yas antacid salt.
The modernisation of injectable section by putting Tunnel System and other modern equipments and expansion of tablet department by
putting high speed mega press machines was completed in 2002. The Company carried out an expansion program of the installed
capacities of its manufacturing unit at Pithampur, Dist. Dhar to increase the capacity of tablet section by 35% and also doubling of the
capacity of capsule section. Capacity of packing section was increased in line with the increase in capacity of the said formulation
sections. The expansion cum modernization program was implemented at a total cost of Rs. 1.34 crore out of which the major expenditure was incurred in 2002-03. The expanded capacities were made available for production from May, 2003.
In 2007, the Company launched a new division 'Cratus Life Care' to expand its operations. The expansion cum modernization project at Pithampur unit was completed with the total investment costing Rs 15.17 Crore during the year 2007-08. The Company raised long term financial resources by way of preference issuance of 3,10,000 equity shares of Rs.10 each at a premium of Rs.36 per share on 29 March, 2008 to the promoters of the Company and the said Equity got listed with the BSE in 2008.
In 2020-21, the business activity of the Company was expanded by increasing the overall production capacity of Injectable capacity from 200 Lakhs to 300 Lakhs per annum and to modernize the Tablet Department within an overall cost of Rs. 4031.50 Lakhs which
was funded by the issuance of fresh share capital to meet the overall cost of the project.
The share price of Syncom Formulations (India) Ltd for NSE is ₹ 16.32 and for BSE is ₹ 16.4.
The market cap of Syncom Formulations (India) Ltd for NSE is ₹ 15,34.08 Cr. and for BSE is ₹ 15,41.60 Cr. as of now.
The 52 Week High and Low of Syncom Formulations (India) Ltd for NSE is ₹ 27.90 and ₹ 10.95 and for BSE is ₹ 27.94 and ₹ 11.00.
You can trade in Syncom Formulations (India) Ltd shares with Bajaj Broking by opening a Demat Account.
The 1 year returns on the stock has been 21.37%.
Syncom Formulations (India) Ltd share price is for NSE ₹ 16.32 & for BSE ₹ 16.4 as on Apr 30 2025 03:30 PM.
The market cap of Syncom Formulations (India) Ltd for NSE ₹ 15,34.08 & for BSE ₹ 15,41.60 as on Apr 30 2025 03:30 PM.
As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Syncom Formulations (India) Ltd share is 40.98.
As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Syncom Formulations (India) Ltd share is 3.31.
You can trade in Syncom Formulations (India) Ltd shares with Bajaj Broking by opening a demat account.
To buy Syncom Formulations (India) Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Syncom Formulations (India) Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found